Jon J Rasmussen1, Morten Schou2, Per L Madsen3, Christian Selmer4, Marie L Johansen5, Peter S Ulriksen6, Tina Dreyer4, Thomas Kümler3, Louis L Plesner3, Jens Faber5, Finn Gustafsson7, Caroline Kistorp5. 1. Centre of Endocrinology and Metabolism, Department of Internal Medicine, Copenhagen University Hospitals Herlev/Gentofte, Herlev, Denmark; Institute of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark. Electronic address: jon.ras@dadlnet.dk. 2. Institute of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark; Department of Cardiology, Copenhagen University Hospitals Herlev/Gentofte, Herlev, Denmark. 3. Department of Cardiology, Copenhagen University Hospitals Herlev/Gentofte, Herlev, Denmark. 4. Centre of Endocrinology and Metabolism, Department of Internal Medicine, Copenhagen University Hospitals Herlev/Gentofte, Herlev, Denmark. 5. Centre of Endocrinology and Metabolism, Department of Internal Medicine, Copenhagen University Hospitals Herlev/Gentofte, Herlev, Denmark; Institute of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark. 6. Department of Radiology, Copenhagen University Hospitals, Herlev/Gentofte, Herlev, Denmark. 7. Institute of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark; Department of Cardiology, Heart Centre, Copenhagen University Hospital Rigshospitalet, Copenhagen, Denmark.
Abstract
Background: Illicit use of anabolic androgenic steroids (AAS) is associated with left ventricle (LV) systolic dysfunction and increased LV mass (LVM), but whether these findings persist in former AAS users has yet to be elucidated. The objective was to assess LV systolic function, LVM and myocardial fibrosis in current and former illicit AAS users compared with non-users. Methods: Community-based cross-sectional study among men, aged 18–50 years, involved in recreational resistance training. We included 37 current and 33 former illicit AAS users, geometric mean (95%CI), 30 (21; 44) months since AAS cessation, and 30 non-users as controls. We assessed myocardial function and structure using advanced echocardiography and cardiac MRI with late-gadolinium enhancement. Results: Mean (SE) LV global longitudinal strain (GLS) was impaired in former AAS users compared with non-users, −16.7 (0.5) versus −18.2 (0.4) %, P < .05. Mean (SE) LV ejection fraction (EF) was decreased, 51 (1) versus 58 (1) %, P < .001 and LV GLS impaired, −14.5 (0.4)%, P < .001, in current AAS users compared with non-users. Measures of LVM were increased in current AAS users compared with the other two groups, P < .001. Plasma total testosterone was independently associated with reduced LVEF (P = .049) and increased LVM/body surface area (P = .005) in multivariate linear regressions. Focal myocardial fibrosis was not detected in any participants and diffuse myocardial fibrosis, assessed using post-contrast T1-mapping time, did not differ among the three groups. Conclusions: Past illicit AAS use is associated with impaired LV GLS, suggesting subclinical cardiac systolic dysfunction years after AAS cessation.
Background: Illicit use of anabolic androgenic steroids (AAS) is associated with left ventricle (LV) systolic dysfunction and increased LV mass (LVM), but whether these findings persist in former AAS users has yet to be elucidated. The objective was to assess LV systolic function, LVM and myocardial fibrosis in current and former illicit AAS users compared with non-users. Methods: Community-based cross-sectional study among men, aged 18–50 years, involved in recreational resistance training. We included 37 current and 33 former illicit AAS users, geometric mean (95%CI), 30 (21; 44) months since AAS cessation, and 30 non-users as controls. We assessed myocardial function and structure using advanced echocardiography and cardiac MRI with late-gadolinium enhancement. Results: Mean (SE) LV global longitudinal strain (GLS) was impaired in former AAS users compared with non-users, −16.7 (0.5) versus −18.2 (0.4) %, P < .05. Mean (SE) LV ejection fraction (EF) was decreased, 51 (1) versus 58 (1) %, P < .001 and LV GLS impaired, −14.5 (0.4)%, P < .001, in current AAS users compared with non-users. Measures of LVM were increased in current AAS users compared with the other two groups, P < .001. Plasma total testosterone was independently associated with reduced LVEF (P = .049) and increased LVM/body surface area (P = .005) in multivariate linear regressions. Focal myocardial fibrosis was not detected in any participants and diffuse myocardial fibrosis, assessed using post-contrast T1-mapping time, did not differ among the three groups. Conclusions: Past illicit AAS use is associated with impaired LV GLS, suggesting subclinical cardiac systolic dysfunction years after AAS cessation.
Authors: Andreas Breenfeldt Andersen; Glenn A Jacobson; Jacob Bejder; Dino Premilovac; Stephen M Richards; Jon J Rasmussen; Søren Jessen; Morten Hostrup Journal: Sports Med Date: 2021-04-02 Impact factor: 11.136
Authors: Giuseppe Davide Albano; Francesco Amico; Giuseppe Cocimano; Aldo Liberto; Francesca Maglietta; Massimiliano Esposito; Giuseppe Li Rosi; Nunzio Di Nunno; Monica Salerno; Angelo Montana Journal: Healthcare (Basel) Date: 2021-01-19
Authors: Björn Gunnarsson; Artin Entezarjou; Fernando Fernández-Aranda; Susana Jiménez-Murcia; Göran Kenttä; Anders Håkansson Journal: Front Sports Act Living Date: 2022-08-01
Authors: Evangelia Joseph Kouidi; Antonia Kaltsatou; Maria Apostolos Anifanti; Asterios Pantazis Deligiannis Journal: Int J Environ Res Public Health Date: 2021-06-29 Impact factor: 3.390